Vanna Chiarion‐Sileni
Istituto Oncologico Veneto
Affiliation Istituto Oncologico Veneto Top Publications Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (2015) – 8,295 citations Nivolumab in Previously Untreated Melanoma without BRAF Mutation (2014) – 5,466 citations Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) – 5,461 citations Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma ... <a title="Vanna Chiarion‐Sileni" class="read-more" href="https://journalsworld.com/researchers/vanna-chiarion%e2%80%90sileni/" aria-label="Read more about Vanna Chiarion‐Sileni">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Istituto Oncologico Veneto
Top Publications
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (2015) - 8,295 citations
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation (2014) - 5,466 citations
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) - 5,461 citations
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2019) - 3,810 citations
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) - 3,026 citations
At a glance
- Full name
- Vanna Chiarion‐Sileni
- ORCID
- 0000-0001-9191-9124
- OpenAlex ID
- https://openalex.org/A5031591368
Research interests
- Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Immunotherapy and Immune Responses
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma ↗2015 · New England Journal of Medicine8,295OpenAlex citations
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation ↗2014 · New England Journal of Medicine5,466OpenAlex citations
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma ↗2017 · New England Journal of Medicine5,461OpenAlex citations
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma ↗2019 · New England Journal of Medicine3,810OpenAlex citations
- 3,026OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma ↗2015 · New England Journal of Medicine
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation ↗2014 · New England Journal of Medicine
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma ↗2017 · New England Journal of Medicine
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma ↗2019 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 23:02:04
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.